Abstracts Archive - Page 2570 of 2607 - ACR Meeting Abstracts

Abstract Number: 498 • 2012 ACR/ARHP Annual Meeting
LIGHT (TNFSF14), Cathepsin-K, DKK-1 and Sclerostin in Rheumatoid Arthritis Patients: Effect of ANTI TNF-α Treatment in the WNT/β-Catenin Network Signaling
Alberto Cauli¹, Grazia Dessole¹, Giovanni Porru¹, Matteo Piga¹, Alessandra Vacca², Valentina Ibba¹, Pietro Garau¹ and Alessandro Mathieu¹, ¹Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ²Rheumatology Unit - Medical Sciences, University of Cagliari, Cagliari, Italy
Background/Purpose: We previously reported increased expression of cell membrane RANKL in PBMC of patients with active rheumathoid arthritis (RA) which was down-regulated by anti TNF-α…
Abstract Number: 499 • 2012 ACR/ARHP Annual Meeting
What Is the Right Dose to Start Methotrexate (7.5 or 15mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial)
Varun Dhir¹, Mandeep Singla², Palvi Goyal², Vinay Sagar², Aman Sharma¹ and Shefali K. Sharma², ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Internal Medicine (Rheumatology Unit), Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Recent recommendations have suggested higher starting doses of methotrexate, i.e. 15 mg/week (3E initiative) in rheumatoid arthritis. However, studies comparing conventional (7.5mg) and newer…
Abstract Number: 500 • 2012 ACR/ARHP Annual Meeting
Comparison of Tolerability Between Tumor Necrosis Factor-Inhibitors and Tocilizumab for the Treatment of Rheumatoid Arthritis
Yoshihiro Hishitani¹, Yoshihito Shima¹, Toru Hirano¹, Keisuke Hagihara², Kosuke Ebina³, Yasuo Kunugiza⁴, Kenrin Shi³, Masashi Narazaki¹, Atsushi Ogata¹, Tetsuya Tomita⁵, Toshio Tanaka¹ and Atsushi Kumanogoh¹, ¹Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, ²Department of Kampo Medicine, Osaka University Graduate School of Medicine, Suita, Japan, ³Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ⁴Orthopedics, Osaka University Graduate School of Medicine, Suita, Japan, ⁵Dept of Orthopaedics, Osaka University Graduate School of Medicine, Suita, Japan
Background/Purpose: Some patients with rheumatoid arthritis (RA) receiving tumor necrosis factor-inhibitors (TNF-Is) show inadequate response to TNF-Is. But it has not been clarified what is…
Abstract Number: 501 • 2012 ACR/ARHP Annual Meeting
TNF Inhibitor Treatment in Rheumatoid Arthritis (RA) Patients with Moderate Versus High Disease Activity At Baseline: A Comparison of Utility Gains, Response and Remission Rates
Elisabeth Lie, Siri Lillegraven, Karen M. Fagerli, Till Uhlig and Tore K. Kvien, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Randomized clinical trials in RA have until recently focused on patients (pts) with high disease activity, but the majority of pts in the clinic…
Abstract Number: 502 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis and Lung Involvement
Elena Becerra¹, Geraldine Cambridge² and Maria J. Leandro², ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Lung involvement is common in patients with Rheumatoid Arthritis (RA), including interstitial lung disease (ILD), pleural disease and small airway disease. There are no…
Abstract Number: 503 • 2012 ACR/ARHP Annual Meeting
Safety Update On Certolizumab Pegol in Patients with Active Rheumatoid Arthritis with Long Term Exposure
Xavier Mariette¹, RF. van Vollenhoven², Vivian P. Bykerk³, Marc de Longueville⁴, Catherine Arendt⁴, Kristel Luijtens⁵ and John J. Cush⁶, ¹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ²Clinical Trials Unit Department of rheumatology, The Karolinska Institute, Stockholm, Sweden, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Global Medical Affairs, UCB Pharma, Brussels, Belgium, ⁵UCB Pharma, Brussels, Belgium, ⁶Baylor Research Institute, Dallas, TX
Background/Purpose: The safety of certolizumab pegol (CZP) in rheumatoid arthritis (RA) has been reported in previous pooled analyses of clinical trials. An update of long-term…
Abstract Number: 504 • 2012 ACR/ARHP Annual Meeting
Pathogenic Autoantibodies to the Anti-Muscarinic Type 3 Receptor Act by Competitive Inhibition of Acetylcholine-Mediated Receptor Signalling in Sjögren’s Syndrome
Michael W. Jackson¹, Isabell Bastian² and Thomas P. Gordon³, ¹Immunology, Flinders University, Adelaide, Australia, ²Immunology, Allergy and Arthritis, Flinders University and Flinders Medical Centre, Adelaide, Australia, ³Immunology Allergy & Arthritis, Flinders Medical Centre, Bedford Park, Australia
Background/Purpose: Primary Sjögren’s syndrome (SS) is a systemic autoimmune disorder characterized by exocrine failure and widespread autonomic dysfunction. Functional autoantibodies (Abs) directed against the muscarinic…
Abstract Number: 505 • 2012 ACR/ARHP Annual Meeting
Characterization of an in Vitro Model of Human Salivary Gland for Studying Sjögren Syndrome (SS)
M. Jesus Dominguez-Luis¹, M.Teresa Arce-Franco¹, Estefania Armas-Gonzalez¹, Ada Herrera-Garcia¹, Teresa Giraldez², Pablo Miranda², Diego Alvarez de la Rosa³, Jose Garcia-Verdugo⁴, Carlos Martinez-Jimeno⁵ and Federico Diaz-Gonzalez¹, ¹Rheumatology Service. Hospital Universitario de Canarias., La Laguna, Spain, ²Unidad de Investigación of Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain, ³Department of Physiology. Universidad de La Laguna,, La Laguna, Spain, ⁴Cellular Morphology Laboratory, Centro de Investigación Príncipe Felipe., Valencia, Spain, ⁵Maxilofacial Department, Hospital Universitario de Canarias,, La Laguna, Spain
Background/Purpose: Sjögren's syndrome (SS) is an autoimmune exocrinopathy of unknown etiology that is characterized by decreased salivary secretion (xerostomy) and lacrimal (xerophthalmy). Histopathological lesions…
Abstract Number: 506 • 2012 ACR/ARHP Annual Meeting
Ebv-Mir-Bart13 Affects the Expression of AQP5 in Human Salivary Gland Cell Lines Contributing to the Pathogenesis of Sjögren’s Syndrome
Alessia Gallo¹, Mayank Tandon¹, Shyh-Ing Jang², Hwei Ling Ong², Indu Ambudkar², Gabor G. Illei³ and Ilias Alevizos⁴, ¹Sjogren's Clinic, NIDCR, Bethesda, MD, ²Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, ³Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD, ⁴Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD
Background/Purpose: Loss of secretory function of salivary glands is one of the most important functional effects of Sjögren’s syndrome (SS), a chronic systemic autoimmune disease.…
Abstract Number: 507 • 2012 ACR/ARHP Annual Meeting
Expression of Micrornas (miRNAs) Predicted to Target Ro/SSA and La/SSB Autoantigens in Sjögren’s Syndrome (SS)
Vasiliki C. Gourzi¹, Efstathia K. Kapsogeorgou¹, Nikolaos C. Kyriakidis¹, Menelaos N. Manoussakis¹, Haralampos M. Moutsopoulos² and Athanasios G. Tzioufas³, ¹Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ²Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ³Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: microRNAs (miRNAs) are key post-transcriptional regulators of gene expression and might be implicated in the over-expression of Ro/SSA and La/SSB autoantigens in the salivary…
Abstract Number: 508 • 2012 ACR/ARHP Annual Meeting
TLR3-Signaling Induces the Expression of Ro/SSA and La/SSB Autoantigens in Salivary Gland Epithelial Cells (SGECs)
Nikolaos C. Kyriakidis¹, Efstathia K. Kapsogeorgou¹, Vasiliki C. Gourzi¹, Haralampos M. Moutsopoulos² and Athanasios G. Tzioufas³, ¹Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ²Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ³Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: Previous studies have shown that the mRNA expression levels of the Ro52/TRIM21, Ro60/TROVE2 and La/SSB intracellular autoantigens are elevated within the immunopathologic lesions of…
Abstract Number: 509 • 2012 ACR/ARHP Annual Meeting
IL-7 and Toll-Like Receptor 7 Synergistically Increase Th1/Th17/Th22 Cytokine Secretion and Activity of B Cells
A. Bikker¹, A.a. Kruize¹, F. Redegeld², W. de Jager³, F.P.J.G. Lafeber⁴ and J.A.G. van Roon⁵, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Dept Pharmacology UU, Utrecht, Netherlands, ³Dept Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: IL-7 is a potent T cell activating cytokine that has been shown to cause proliferation, survival and differentiation of T cells as well as…
Abstract Number: 470 • 2012 ACR/ARHP Annual Meeting
Concomitant Assessment of Clinical and Ultrasound Efficacy and Safety of Tocilizumab in Patients with Moderate to Severe Rheumatoid Arthritis: The Torpedo Study
Thierry Schaeverbeke¹, Philippe Gaudin², Aleth Perdriger³, Christian Roux⁴, Muriel Vray⁵, Stephanie Rouanet⁶, Ghislaine Steinberg⁷ and Fabien Etchepare⁸, ¹Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ²Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ³Rheumatology, Hôpital Sud, Rennes, France, ⁴Rheumatology, Paris Descartes University, Paris, France, ⁵Institut Pasteur, Paris, France, ⁶Medical Department, Roche, Boulogne, France, ⁷Medical department, Roche, Boulogne, France, ⁸G.H. Pitié-Salpêtrière, Paris, France
Background/Purpose: The anti-IL6-R tocilizumab (TCZ), indicated for the treatment of moderate to severe rheumatoid arthritis (RA), has demonstrated its clinical and structural efficacy in phase…
Abstract Number: 471 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Golimumab As Add-On Therapy to Disease-Modifying Antirheumatic Drugs
Bernard Combe¹, Bhaskar Dasgupta², Ingrid Louw³, Sarvajeet Pal⁴, Jürgen Wollenhaupt⁵, Cristiano Zerbini⁶, Andre D. Beaulieu⁷, Hendrik Schulze-Koops⁸, Patrick Durez⁹, Ruji Yao¹⁰, Nathan Vastesaeger¹¹ and Holly Weng¹⁰, ¹Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, ²Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Advance Rheumatology Clinic, Hyderabad, India, ⁵Schön-Klinik, Hamburg, Germany, ⁶Centro Paulista de Investigações, Sao Paulo, Brazil, ⁷Bureau 140, Centre de Rhumatologie, St. Louis, QC, Canada, ⁸University of Munich, Munich, Germany, ⁹UCL Saint-Luc, Brussels, Belgium, ¹⁰Merck Sharp & Dohme, Kenilworth, NJ, ¹¹Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: This study evaluated golimumab (GLM) as add-on therapy in patients with active RA despite treatment with non-biologic DMARDs. Two GLM treatment strategies (subcutaneous [SC]…
Abstract Number: 472 • 2012 ACR/ARHP Annual Meeting
More Positive Expectations of Treatment with Golimumab for Rheumatoid Arthritis Are Associated with Greater Improvement in Clinical Outcomes
Bhaskar Dasgupta¹, Bernard Combe², Ingrid Louw³, Sarvajeet Pal⁴, Jürgen Wollenhaupt⁵, Cristiano Zerbini⁶, Andre D. Beaulieu⁷, Hendrik Schulze-Koops⁸, Patrick Durez⁹, W. Bensen¹⁰, V. Wolff¹¹, Ruji Yao¹², Holly Weng¹² and Nathan Vastesaeger¹³, ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Advance Rheumatology Clinic, Hyderabad, India, ⁵Schön-Klinik, Hamburg, Germany, ⁶Centro Paulista de Investigações, Sao Paulo, Brazil, ⁷Bureau 140, Centre de Rhumatologie, St. Louis, QC, Canada, ⁸University of Munich, Munich, Germany, ⁹UCL Saint-Luc, Brussels, Belgium, ¹⁰St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ¹¹Hospital del Salvador, Santiago, Chile, ¹²Merck Sharp & Dohme, Kenilworth, NJ, ¹³Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Little is known about how patient and physician expectations relate to clinical outcomes. This study investigated the expectations that patients and physicians have at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].